Geneuro Logo

Geneuro

GEM | PA

Overview

Corporate Details

ISIN(s):
CH0308403085
LEI:
213800FUJCKXO9LK3444
Country:
Switzerland
Address:
chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

GeNeuro is a Swiss-based, clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and autoimmune diseases. The company utilizes a novel therapeutic approach that targets pathogenic proteins encoded by human endogenous retroviruses (HERVs), which are believed to contribute to the progression of diseases such as Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and post-COVID conditions. Its main drug candidate, temelimab, is being developed to treat the cognitive and fatigue symptoms associated with Long COVID. In July 2024, the company was granted a debt-restructuring moratorium.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Geneuro. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-30 19:37
Post-Annual General Meeting Information
Inside Information / Other news releases
English 224.5 KB
2025-06-30 19:37
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 753.1 KB
2025-06-12 22:42
Legal Proceedings Report
Inside Information / Other news releases
English 204.9 KB
2025-06-12 22:42
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 203.8 KB
2025-06-10 18:24
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 207.4 KB
2025-06-10 18:24
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 209.5 KB
2025-05-27 18:00
Legal Proceedings Report
Inside Information / Other news releases
English 162.5 KB
2025-05-27 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 187.1 KB
2025-05-12 18:36
Report Publication Announcement
Inside Information / Other news releases
English 481.8 KB
2025-05-12 18:36
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 669.5 KB

Automate Your Workflow. Get a real-time feed of all Geneuro filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Geneuro via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genmab Logo
Develops antibody therapeutics for cancer and serious diseases using proprietary technology.
Denmark GMAB
Genomic Vision Logo
Develops DNA analysis tools using Molecular Combing for genetic research and diagnostics.
France GV
genOway Logo
Develops genetically engineered preclinical models for biopharma and academic research.
France ALGEN
GenSight Biologics S.A. Logo
Biopharma developing gene therapies for retinal neurodegenerative diseases and CNS disorders.
France SIGHT
Genxone Spolka Akcyjna Logo
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland GX1
Guard Therapeutics International AB Logo
Clinical-stage biotech developing protein-based therapies for acute kidney injury.
Sweden GUARD
Gubra A/S Logo
Preclinical CRO and peptide drug developer for metabolic and fibrotic diseases.
Denmark GUBRA
Hamlet BioPharma AB Logo
Developing selective therapies for cancer and infections like bladder cancer and UTIs.
Sweden HAMLET
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops novel therapies for life-threatening blood disorders, cancers, and autoimmune diseases.
United Kingdom HEMO
Herantis Pharma Oyj Logo
Clinical-stage biotech developing therapies for neurodegenerative disorders like Parkinson's.
Finland HRTIS